Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Liver Neoplasms 1Head and Neck Neoplasms 1Fibrosis 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Enkephalin, Methionine × Clear all
NCT00783172 2018-09-06

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

Milton S. Hershey Medical Center

Phase 1 Terminated
4 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00255333 2007-05-14

INNO-105 in Patients With Solid Tumors

Innovive Pharmaceuticals

Phase 1 Terminated
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡